As Ironwood Pharmaceuticals INC (IRWD) Stock Value Rose, Sarissa Capital Management LP Increased Position

August 8, 2018 - By Alfred Lee

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) LogoInvestors sentiment decreased to 0.7 in Q1 2018. Its down 0.35, from 1.05 in 2017Q4. It fall, as 20 investors sold IRWD shares while 50 reduced holdings. 19 funds opened positions while 30 raised stakes. 150.40 million shares or 0.28% more from 149.98 million shares in 2017Q4 were reported. Art Ltd Llc owns 13,493 shares. Great West Life Assurance Can owns 14,842 shares. Metropolitan Life Ins reported 43,841 shares. Bnp Paribas Asset Mngmt Sa reported 1.70 million shares. Amalgamated Bancshares, New York-based fund reported 18,014 shares. Evercore Wealth Limited Liability owns 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 22,425 shares. Rhumbline Advisers stated it has 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Alps Advsrs holds 0.02% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 181,590 shares. Moreover, Fisher Asset Management Limited Liability Corporation has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Bvf Incorporated Il has 8.67% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 5.54M shares. Barclays Public Limited Liability Corporation invested in 0% or 33,180 shares. Manufacturers Life Ins The has 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 100,509 shares. Tocqueville Asset Mngmt Limited Partnership owns 29,612 shares for 0.01% of their portfolio. Parallax Volatility Advisers Ltd Partnership invested in 0% or 48,366 shares. Bancshares Of America De owns 213,730 shares or 0% of their US portfolio.

Since February 21, 2018, it had 0 insider buys, and 10 selling transactions for $1.53 million activity. 2,000 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares with value of $28,100 were sold by OLANOFF LAWRENCE S. Currie Mark G also sold $23,954 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, February 21. On Wednesday, February 21 Consylman Gina sold $52,688 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 3,594 shares. $21,090 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares were sold by McHugh Julie. MCCOURT Thomas A sold $600,000 worth of stock.

Sarissa Capital Management Lp increased its stake in Ironwood Pharmaceuticals Inc (IRWD) by 104.07% based on its latest 2018Q1 regulatory filing with the SEC. Sarissa Capital Management Lp bought 1.72M shares as the company’s stock rose 15.37% while stock markets declined. The hedge fund held 3.37 million shares of the health care company at the end of 2018Q1, valued at $51.95 million, up from 1.65M at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Ironwood Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.88 billion market cap company. It closed at $18.97 lastly. It is down 9.49% since August 8, 2017 and is downtrending. It has underperformed by 22.06% the S&P500.

Sarissa Capital Management Lp, which manages about $595.73 million and $432.14 million US Long portfolio, decreased its stake in Achillion Pharmaceuticals Inc (NASDAQ:ACHN) by 2.00 million shares to 500,000 shares, valued at $1.86 million in 2018Q1, according to the filing.

More notable recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on July 23, 2018, also Nasdaq.com with their article: “Ironwood Begins New Phase III Study to Expand Linzess Label” published on July 17, 2018, Seekingalpha.com published: “Ironwood Pharmaceuticals, Inc. (IRWD) CEO Peter Hecht on Q2 2018 Results – Earnings Call Transcript” on August 06, 2018. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) were released by: Seekingalpha.com and their article: “Ironwood launches late-stage study of linaclotide in IBS-C; shares up 3% premarket” published on July 16, 2018 as well as Seekingalpha.com‘s news article titled: “Ironwood Pharma Q2 revenues up 25%” with publication date: August 06, 2018.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Ratings Coverage

Among 7 analysts covering Ironwood Pharma (NASDAQ:IRWD), 3 have Buy rating, 2 Sell and 2 Hold. Therefore 43% are positive. Ironwood Pharma had 9 analyst reports since March 12, 2018 according to SRatingsIntel. The firm has “Market Perform” rating given on Wednesday, July 18 by Cowen & Co. On Wednesday, May 9 the stock rating was downgraded by Morgan Stanley to “Underweight”. The company was maintained on Monday, March 12 by Mizuho. The firm earned “Outperform” rating on Thursday, May 31 by Wells Fargo. Berenberg initiated it with “Buy” rating and $2500 target in Thursday, April 19 report. On Wednesday, May 2 the stock rating was upgraded by Mizuho to “Buy”. The stock has “Buy” rating by Mizuho on Thursday, May 31.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: